Microbot Medical (MBOT)
(Delayed Data from NSDQ)
$0.94 USD
-0.02 (-2.39%)
Updated Sep 17, 2024 04:00 PM ET
After-Market: $0.94 0.00 (0.31%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth F Momentum C VGM
Price, Consensus and EPS Surprise
MBOT 0.94 -0.02(-2.39%)
Will MBOT be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for MBOT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MBOT
Microbot Medical (MBOT) Inks New Phase 2 Agreement for LIBERTY
Microbot Medical (MBOT) Gets Quality Certification for its System
MBOT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Microbot Medical (MBOT) Inks Deal to Test Autonomous Robotics
Microbot Medical (MBOT) Progresses in Its Human Clinical Trial
Microbot Medical (MBOT) Inks Agreement to Begin LIBERTY Trial
Other News for MBOT
Microbot Medical Announces the Successful Enrollment of 50% of the Patients in its Pivotal Human Clinical Trial for the LIBERTY Endovascular Robotic Surgical System
Microbot Medical Advances in Endovascular Robotic Trials
Microbot Medical announces enrollment of 50% of patients in ACCESS-PVI trial
Microbot Medical signs Phase 2 agreement with Corewell Health
Microbot Medical Signs Phase 2 Collaboration Agreement with Corewell Health to Advance Remote Telesurgery Using the LIBERTY? Endovascular Robotic System